Three year IGF-I treatment of children with Laron syndrome

J Pediatr Endocrinol Metab. Jul-Sep 1995;8(3):149-58. doi: 10.1515/jpem.1995.8.3.149.

Abstract

Nine prepubertal children with Laron syndrome (6 males, 3 females) aged 0.5 to 14.6 years were treated by daily subcutaneous injections of IGF-I in doses of 150-200 micrograms/kg. All patients completed at least one year of treatment; six completed two years and five three years. During the first year, a significant increase in linear growth velocity, from a mean +/- SD of 4.7 +/- 1.3 to 8.2 +/- 0.8 cm/yr (p < 0.0001), was registered. In the second year the growth velocity was lower, but still significantly higher than before treatment. Bone maturation advanced proportionally with chronological age. A reduction in subcutaneous fat tissue was observed despite the body weight increase. There was no aggravation of the characteristic hypoglycemic episodes; on the contrary, there was a better tolerance to fasting. Significant increases in serum alkaline phosphatase, phosphorus and procollagens were registered throughout the study. In conclusion, IGF-I provides an effective replacement treatment for IGF-I-deficient children, mimicking most effects ascribed to growth hormone.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Body Height / physiology
  • Body Weight / physiology
  • Bone Development / drug effects
  • Bone Development / physiology
  • Bone and Bones / metabolism
  • Child
  • Child, Preschool
  • Female
  • Growth Disorders / metabolism
  • Growth Disorders / pathology
  • Growth Disorders / therapy*
  • Growth Hormone / physiology*
  • Heart Rate / physiology
  • Humans
  • Infant
  • Injections, Subcutaneous
  • Insulin-Like Growth Factor I / deficiency*
  • Insulin-Like Growth Factor I / therapeutic use*
  • Male
  • Recombinant Proteins / therapeutic use
  • Skinfold Thickness
  • Syndrome
  • Time Factors

Substances

  • Recombinant Proteins
  • Insulin-Like Growth Factor I
  • Growth Hormone